Financings Of The Fortnight: Bluebird IPO Could Provide Validation For Gene Therapy As A Modality
This article was originally published in The Pink Sheet Daily
During a year in which biotech IPOs have taken off, the bluebird bio issue calls for special attention. Plus news on recent financings by Quintiles, Portola, Isis and Lumena.
You may also be interested in...
Deal-Making, Financing Coalesce Around Promising CAR-T Space In Cancer
A huge IPO for Kite Pharma and two massive venture rounds for Juno Therapeutics have those two newer companies out in front in CAR therapeutics, but bigger, more established firms like Novartis, Pfizer and Celgene are in the game, while other companies, like biotech Bellicum, are looking to get in. Can Kite and Juno stay ahead and stand alone?
Cellular And Gene Therapy Trial Design: Draft Guidance Highlights Risks
FDA provides advice on designing early-phase trials to assess safety, tolerability and feasibility of administering cellular therapy and gene therapy products but stresses the unique risks of these products.
Curative Regenerative Drugs Need NICE Rethink, Key U.K. Committee Says
Health systems and health technology assessment bodies are unprepared for potentially curative gene and cell therapies, leaving drug makers and researchers in the dark, says influential U.K. parliamentary group.